App-Guided Tapering Raises PPI Discontinuation From 64% to 86% Versus Brochure
This first randomised trial of a smartphone app for proton pump inhibitor (PPI) deprescribing shows a large effect on self-reported discontinuation, but the open-label design, sample size revision and self-reported outcome temper how far pharmacists can extrapolate it.
📅 Journal publication: Oct 2026·Last updated: Oct 22, 2026
App proves superior in discontinuing unnecessary PPI use.
Proton pump inhibitors (PPIs) are commonly overused, making discontinuation challenging. Addressing this gap can optimize therapy. An app led to 86% successful PPI discontinuation versus 64% with a brochure, showing significant improvement (p = 0.002). Utilizing a digital app for PPI discontinuation could enhance outpatient deprescribing efforts. However, adaptation to different healthcare systems is needed. App-based interventions significantly improve PPI discontinuation rates compared to traditional information methods.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.